TET2 and acute myeloid leukemia: Our results show that molecular minimal residual disease (MRD) in non‐IDATE genes (non‐ IDH1/2, DNMT3A, ASXL1, TET2, and EZH2) in bone marrow specimens biopsied within 30 days prior to ASCT predicts worse outcome in AML compared to IDATE mutations.